- Home
- RY vs SNY Comparison
RY vs SNY Comparison
Compare RY & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RY | SNY |
|---|---|---|
| Founded | 1864 | 1994 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.5B | 119.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RY | SNY |
|---|---|---|
| Price | $171.21 | $48.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $162.00 | $61.50 |
| AVG Volume (30 Days) | 983.6K | ★ 2.4M |
| Earning Date | 12-03-2025 | 01-29-2026 |
| Dividend Yield | 2.54% | ★ 3.30% |
| EPS Growth | 25.07 | ★ 105.93 |
| EPS | ★ 10.04 | 8.67 |
| Revenue | $44,415,504,717.00 | ★ $53,890,648,839.00 |
| Revenue This Year | $16.04 | $1.73 |
| Revenue Next Year | $5.00 | $6.49 |
| P/E Ratio | $16.85 | ★ $11.05 |
| Revenue Growth | ★ 15.03 | N/A |
| 52 Week Low | $106.10 | $44.62 |
| 52 Week High | $172.38 | $60.12 |
Technical Indicators
Market Signals| Indicator | RY | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 74.53 | 48.34 |
| Support Level | $169.50 | $48.16 |
| Resistance Level | $172.38 | $48.95 |
| Average True Range (ATR) | 1.79 | 0.58 |
| MACD | -0.08 | 0.11 |
| Stochastic Oscillator | 84.98 | 72.69 |
Price Performance
Historical ComparisonAbout RY Royal Bank Of Canada
Royal Bank of Canada is one of the two largest banks in Canada, with around CAD 2.2 trillion in assets. It is a diversified financial services company, offering personal and commercial banking, wealth management, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada and has dominant market shares. RBC also has wealth and capital market businesses in the US, UK, and other countries. RBC is a top 15 investment bank globally.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.